Founded in 2007, Kips Bay Medical is a medical device company focused on providing therapeutic vascular technologies that help cardiac surgeons better treat cardiovascular disease (NYSE:CVD). Causing one out of every six deaths in the U.S., CVD effects an estimated 82 million Americans. In the 27 member states of the EU, the disease contributes to over 2 million deaths a year.
eSVS Mesh, the company's first commercial product, is used in coronary artery bypass grafting surgery. When placed over a saphenous vein graft during CABG surgery, eSVS Mesh can improve the structural characteristics and long-term performance of the saphenous vein graft. This simple, easy-to-use device is designed to optimize patient outcomes without adding significantly to the time of CABG procedures.
In November, Kips Bay Medical received approval from the FDA to begin clinical study of eSVS Mesh technology in the U.S. The objective of this study is to demonstrate eSVS Mesh's safety and performance. Favorable results are anticipated as the device has already received CE Mark approval and has been successfully implanted in over 400 patients in multiple cardiovascular centers outside of the U.S.
Cardiac surgeons will be eager to start using eSVS Mesh technology in their coronary artery bypass graft (CABG) procedures in order to avoid common problems associated with artery grafts and even outright failure of the corrective surgery. The potential end points for procedure success, patient quality of life, and ensuring long-term viability in the form of external support will be strong commercial drivers for ongoing sales.
For more information, visit kipsbaymedical.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net